Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity

© 2017 Elsevier B.V. Background Prescription Drug Monitoring programs (PDMPs) are intended to reduce opioid prescribing and aberrant drug-related behavior thereby reducing morbidity and mortality due to prescription opioid overdose. Expansion of the New York (NY) State's PDMP in 2013 included t...

Full description

Bibliographic Details
Main Authors: Brown, R., Riley, M., Ulrich, L., Kraly, Ellen, Jenkins, P., Krupa, N., Gadomski, A.
Format: Journal Article
Published: Elsevier Ireland Ltd 2017
Online Access:http://hdl.handle.net/20.500.11937/72123
_version_ 1848762666137419776
author Brown, R.
Riley, M.
Ulrich, L.
Kraly, Ellen
Jenkins, P.
Krupa, N.
Gadomski, A.
author_facet Brown, R.
Riley, M.
Ulrich, L.
Kraly, Ellen
Jenkins, P.
Krupa, N.
Gadomski, A.
author_sort Brown, R.
building Curtin Institutional Repository
collection Online Access
description © 2017 Elsevier B.V. Background Prescription Drug Monitoring programs (PDMPs) are intended to reduce opioid prescribing and aberrant drug-related behavior thereby reducing morbidity and mortality due to prescription opioid overdose. Expansion of the New York (NY) State's PDMP in 2013 included the institution of the I-STOP law that mandated clinicians to consult the statewide PDMP database to review the patient's prescription history prior to prescribing opioids. Methods Trends in prescription opioid distribution, prescribing, and prescription opioid and heroin overdose morbidity in NY were analyzed using time series. A Chow test was used to test the difference in trends before and after the implementation of I-STOP. Results The results indicated that: 1) the number of opioid prescriptions appears to be declining following the implementation of the I-STOP, 2) however, supply chain data shows that the total quantity of opioids in the supply chain increased, 3) statewide trends in inpatient and emergency department visits for prescription opioid overdose increased from 2010 to the third quarter of 2013 where the slope leveled off following I-STOP, but this change in slope was not significant, 4) visits for heroin overdose started escalating in 2010 and continued to increase through the second quarter of 2016. The overall significance of these findings show a small impact of PDMPs on prescription opioid overdose morbidity in NY in the context of the increasing national trend during this time period. Conclusions Prescription opioid morbidity leveled off following the implementation of a mandated PDMP although morbidity attributable to heroin overdose continued to rise.
first_indexed 2025-11-14T10:51:11Z
format Journal Article
id curtin-20.500.11937-72123
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:51:11Z
publishDate 2017
publisher Elsevier Ireland Ltd
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-721232018-12-13T09:32:08Z Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity Brown, R. Riley, M. Ulrich, L. Kraly, Ellen Jenkins, P. Krupa, N. Gadomski, A. © 2017 Elsevier B.V. Background Prescription Drug Monitoring programs (PDMPs) are intended to reduce opioid prescribing and aberrant drug-related behavior thereby reducing morbidity and mortality due to prescription opioid overdose. Expansion of the New York (NY) State's PDMP in 2013 included the institution of the I-STOP law that mandated clinicians to consult the statewide PDMP database to review the patient's prescription history prior to prescribing opioids. Methods Trends in prescription opioid distribution, prescribing, and prescription opioid and heroin overdose morbidity in NY were analyzed using time series. A Chow test was used to test the difference in trends before and after the implementation of I-STOP. Results The results indicated that: 1) the number of opioid prescriptions appears to be declining following the implementation of the I-STOP, 2) however, supply chain data shows that the total quantity of opioids in the supply chain increased, 3) statewide trends in inpatient and emergency department visits for prescription opioid overdose increased from 2010 to the third quarter of 2013 where the slope leveled off following I-STOP, but this change in slope was not significant, 4) visits for heroin overdose started escalating in 2010 and continued to increase through the second quarter of 2016. The overall significance of these findings show a small impact of PDMPs on prescription opioid overdose morbidity in NY in the context of the increasing national trend during this time period. Conclusions Prescription opioid morbidity leveled off following the implementation of a mandated PDMP although morbidity attributable to heroin overdose continued to rise. 2017 Journal Article http://hdl.handle.net/20.500.11937/72123 10.1016/j.drugalcdep.2017.05.023 Elsevier Ireland Ltd restricted
spellingShingle Brown, R.
Riley, M.
Ulrich, L.
Kraly, Ellen
Jenkins, P.
Krupa, N.
Gadomski, A.
Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title_full Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title_fullStr Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title_full_unstemmed Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title_short Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity
title_sort impact of new york prescription drug monitoring program, i-stop, on statewide overdose morbidity
url http://hdl.handle.net/20.500.11937/72123